Reiner v. Teladoc Health, Inc.

CourtDistrict Court, S.D. New York
DecidedNovember 30, 2020
Docket1:18-cv-11603
StatusUnknown

This text of Reiner v. Teladoc Health, Inc. (Reiner v. Teladoc Health, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Reiner v. Teladoc Health, Inc., (S.D.N.Y. 2020).

Opinion

UNITED STATES DISTRICT COURT ELECTRONICALLY FILED DOC #: _________________ SOUTHERN DISTRICT OF NEW YORK DATE FILED: 11/30/20 ------------------------------------------------------------------X JON REINER, individually and on behalf of all others : similarly situated, : : Plaintiff, : 1:18-cv-11603-GHW : -against- : MEMORANDUM OPINION : AND ORDER TELADOC HEALTH, INC., JASON GOREVIC, : and MARK HIRSCHHORN, : : Defendants. : ------------------------------------------------------------------X Defendant Mark Hirschhorn, a senior executive at Defendant Teladoc Health, Inc. (“Teladoc” or the “Company”), had an affair with a low-level employee of the Company. He was promoted to become Chief Operating Officer of the Company in the midst of his affair. When the Company learned of the affair, it launched an investigation and disciplined Hirschhorn. Lead Plaintiffs assert that the Company’s response to the affair was wan, and that the Company retaliated against two of the employees who had reported on the inappropriate relationship. In these ways, Lead Plaintiffs claim, the Company acted in a manner that was not consistent with the Company’s public statements about its ethics policy and program. When the public found out about the relationship, Teladoc’s stock dropped 6.69% percent. As a result, Lead Plaintiffs brought this action. On September 4, 2020, Magistrate Judge Barbara Moses issued a Report and Recommendation (the “R&R”) in response to Defendants’ motion to dismiss the complaint. Dkt. No. 65. Judge Moses recommended that the claims against Defendants be dismissed for failure to allege any materially false or misleading statement because the statements at issue were inactionable puffery. Because the Court agrees with the recommendations provided in the R&R with limited exceptions that do not affect the outcome of this motion, Defendants’ motion to dismiss is GRANTED. I. BACKGROUND The R&R describes in detail the facts and procedural history of this case. The Court refers the reader to the R&R for a more comprehensive description of the facts at issue here, but a short summary is warranted.

Mark Hirschhorn, Executive Vice President (“EVP”), Chief Financial Officer (“CFO”), and eventually Chief Operating Officer (“COO”) at Teladoc, had an “an affair with a low-level employee,” Charece Griffin, beginning in May 2014. Second Amd. Compl. (“SAC”), Dkt. No. 35, ¶ 28. Griffin regularly discussed their relationship with other employees at the Company. Id. at ¶ 5. She “told her coworkers she and Hirschhorn liked to trade [Teladoc’s] stock together” and that he would “tell her when he thought there were good opportunities to sell some shares.” Id. at ¶ 28. On September 28, 2016, Hirschhorn was promoted to COO. Id. at ¶ 26. In October 2016, Griffin’s “ultimate boss,” Amy McKay, submitted an eight-page memorandum to the Teladoc Legal and Human Resources departments describing the “inappropriate relationship” between Hirschhorn and Griffin. Id. at ¶ 6. Teladoc retained an outside law firm to conduct an investigation, which “revealed inappropriate conduct.” Id. at ¶¶ 42–43. In November of that year, the Company’s chief legal officer interviewed McKay. Id. at ¶ 36.

“On December 27, 2016, the Company entered into an amended employment contract with Hirschhorn, with two minor slaps on the wrist: a prohibition from violating the employee handbook (which, presumably, he had never been exempt from following in the first place) and, for a period of one year, a suspension of the scheduled share vesting awarded to him as part of his compensation.” Id. at ¶ 43. After months of “bitterly complaining and arguing with the HR and Legal departments over the [Mark Hirschhorn] decision,” McKay was fired in October 2017. Id. at ¶ 44. Another Teladoc employee was also bullied and ultimately fired by a manager who reported to Hirschhorn after reporting Hirschhorn’s relationship. Id. at ¶ 45. Eventually, on December 5, 2018, the Southern Investigative Research Foundation (“SIRF”) published a report revealing the affair. Id. at ¶ 13. The next day, Teladoc’s stock fell 6.69%. Id.

Plaintiff Jon Reiner initiated this action a week after the SIRF report was published, on behalf of himself and all others who purchased or otherwise acquired Teladoc securities between March 3, 2016 and December 5, 2018. Dkt. No. 1. He named Hirschhorn, Teladoc, and Teladoc’s CEO Jason Gorevic as defendants. After Wayne Arcuri, Badruddin Salimbhai, and David Williams were appointed Lead Plaintiffs, they filed the Second Amended Complaint—the operative pleading. SAC. Lead Plaintiffs allege that Defendants violated § 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), 15 U.S.C. § 78j(b), and Rule 10b-5 promulgated thereunder, 17 C.F.R. § 240.10b-5, by making misleading public statements which were demonstrated to have been false or misleading by Hirschhorn’s misconduct and Teladoc’s tepid response. Id. ¶ 1. The alleged misstatements fall into two categories: statements regarding the Company’s ethics, including Teladoc’s Code of Business Conduct and Ethics (“CBCE”), and risk disclosures regarding its dependence on its senior

management team. Id. ¶¶ 57–80. Defendants moved to dismiss the Second Amended Complaint in its entirety on September 13, 2019. Dkt. No. 46. Judge Moses held oral argument on May 15, 2020. See Tr. of May 15, 2020 Tel. Conf. (“Tr.”), Dkt. No. 63. In her September R&R, Judge Moses recommended that the motion to dismiss be granted because Lead Plaintiffs had failed to allege any material misstatement or omission. R&R at 1. She found that the statements regarding the Company’s code of conduct were “inactionable puffery” and that the key personnel disclosures were not misleading. Id. at 17– 25. Judge Moses did not reach the issue of scienter because she concluded that Lead Plaintiffs had failed to plead any actionable misstatements or omissions. Id. at 26. Because she found that Lead Plaintiffs had not pleaded a primary securities fraud violation, she also recommended dismissing Lead Plaintiffs’ claim for “control person liability” under Section 20(a) of the Exchange Act. Id. Finally, Judge Moses recommended denying leave to amend the complaint. Id. at 27.

On September 18, 2020, Lead Plaintiffs filed timely objections to almost every aspect of the R&R (the “Objections”). Dkt. No. 66. Defendants responded to the Objections on October 2, 2020 (the “Opposition”). Dkt. No. 68. Lead Plaintiffs filed their reply on October 6, 2020. Dkt. No. 69. While the Objections take aim at all of Judge Moses’ recommendations, they focus on her recommended dismissal of the Section 10(b) claims related to statements regarding the Company’s ethics and the CBCE, as well as her denial of leave to amend the complaint. Lead Plaintiffs argue that the context in which Defendants’ statements were made demonstrates the false and misleading nature of Defendants’ alleged misrepresentations. Objections at 10–12. Lead Plaintiffs further argue that Defendants’ statements were not mere aspirational representations, and that even if they were aspirational, they were actionable because they were materially false and misleading. Id. at 12– 21. In lodging the Objections, Lead Plaintiffs argued that Judge Moses inappropriately made factual

determinations and failed to draw plausible inferences in their favor as required on a motion to dismiss, and inaccurately focused on the relationship itself, rather than the Company’s response to that relationship. II. STANDARD OF REVIEW With respect to dispositive motions, the Court may “accept, reject or modify, in whole or in part, the findings or recommendations made by the magistrate judge.” 28 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Basic Inc. v. Levinson
485 U.S. 224 (Supreme Court, 1988)
ATSI Communications, Inc. v. Shaar Fund, Ltd.
493 F.3d 87 (Second Circuit, 2007)
In re Aluminum Warehousing Antitrust Litigation
95 F. Supp. 3d 419 (S.D. New York, 2015)
In re Braskem S.A. Securities Litigation
246 F. Supp. 3d 731 (S.D. New York, 2017)
In re Banco Bradesco S.A. Securities Litigation
277 F. Supp. 3d 600 (S.D. New York, 2017)
Singh v. Cigna Corp.
918 F.3d 57 (Second Circuit, 2019)
Luce v. Edelstein
802 F.2d 49 (Second Circuit, 1986)

Cite This Page — Counsel Stack

Bluebook (online)
Reiner v. Teladoc Health, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/reiner-v-teladoc-health-inc-nysd-2020.